Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04304508 · ClinicalTrials.gov registry record · Phase 2
Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.
A Phase 2 study of Acute Non-cardioembolic Ischemic Stroke, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,808
- Enrollment target
- 20
- Study locations
NCT04304508 is a Phase 2 study of Acute Non-cardioembolic Ischemic Stroke that has completed, run by Bayer. The registered enrollment target is 1,808 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT04304508, a Phase 2 study of Acute Non-cardioembolic Ischemic Stroke, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,808 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of antiplatelet therapy in patients following a recent non cardioembolic ischemic stroke which occurs when a blood clot that has not formed in the heart travelled to the brain. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor.
Conditions Studied
Interventions
- DRUG BAY2433334
- OTHER BAY2433334 matching placebo
Study Locations (20)
Victoria
- Grampians Health Ballarat - Ballarat
- Eastern Clinical Research Unit - Box Hill - Box Hill
- Royal Melbourne Hospital - Parkville
- The Alfred Hospital - Prahran
New South Wales
- Liverpool Hospital - Liverpool
- John Hunter Hospital - New Lambton
- Royal North Shore Hospital - Sydney
Queensland
- Sunshine Coast University Hospital - Birtinya
- Gold Coast University Hospital - Southport
Florida
- Univ.of South Florida College of Medicine - Tampa
Minnesota
- Minneapolis Clinic of Neurology, Ltd. - Golden Valley
Missouri
- St. Luke's Hospital of Kansas City - Kansas City
North Carolina
- Guilford Neurologic Associates - Greensboro
Pennsylvania
- University of Pittsburgh Medical Center Hamot - Erie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,808 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2022-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04304508
The ClinicalTrials.gov registry entry for NCT04304508 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,808 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Non-cardioembolic Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which BAY2433334 is the first listed.
NCT04304508 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Victoria, New South Wales, Queensland.
Frequently Asked Questions
What is clinical trial NCT04304508 about?
NCT04304508 is a clinical study titled "Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.". The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of antiplatelet therapy in patients following a recent non cardioembolic ischemic stroke which occurs when a blood clot that has not formed i...
What is the current status of trial NCT04304508?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,808 participants. The study started on 2020-06-15. Estimated completion is 2022-02-18.
What conditions does trial NCT04304508 study?
This clinical trial studies the following conditions: Acute Non-cardioembolic Ischemic Stroke.
What interventions are being tested in trial NCT04304508?
The interventions under investigation include: BAY2433334 (DRUG), BAY2433334 matching placebo (OTHER).
Who is sponsoring clinical trial NCT04304508?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04304508 being conducted?
This trial has 20 study locations across Florida, Minnesota, Missouri, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Non-cardioembolic Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.